Oxford Biomedica new manufacturing suite approved
Oxford Biomedica
425.00p
12:40 24/12/24
0.00%
0.00p
Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.
FTSE 250
20,571.51
13:00 24/12/24
n/a
n/a
FTSE 350
4,491.87
12:54 24/12/24
n/a
n/a
FTSE All-Share
4,449.61
13:14 24/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
20,055.90
12:54 24/12/24
0.25%
50.73
Approval was given by the UK Medicines & Healthcare products Regulatory Agency, the company said on Tuesday.
“Both this suite and the suite approved in September …at present will be dedicated to the manufacture of a Covid-19 viral vector vaccine candidate,” Oxford said.
“This world class facility is suitable for the manufacture of a variety of viral vectors and the approval of this fourth suite completes a phase of expansion that more than doubles Oxford Biomedica's manufacturing capacity compared to 2019, supporting further growth in revenues and partner programmes.”